1140 материалов по теме, собраны автоматически из проверенных источников
Researchers from City of Hope have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. Published in Cancer Immunology Research, the…
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 Business Wire
What drives time-to-randomization in oncology trials? clinicaltrialsarena.com
CU Anschutz Thyroid Cancer Researchers Get Major Boost from DOD Impact Award University of Colorado Anschutz
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion streetinsider.com
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion PR Newswire
A head-and-neck cancer trial reported 39.3 months of median survival Stock Titan
What drives time-to-randomization in oncology trials? Pharmaceutical Technology
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESM Business Wire
Ivonescimab beats durvalumab in biliary tract cancer Phase III trial The Clinical Trial Vanguard
VHIO celebrates 20 years of driving cancer research VHIO
UMich launches world’s first histotripsy center, advancing non-invasive cancer treatment research The Michigan Daily
Study unveils ‘plug-and-play’ CAR T technology designed to adapt as cancer changes EurekAlert!
How AI Is Influencing Cancer Research and Care Delivery - Sarah Cannon Research Institute Oncodaily
Foundation for Women’s Cancer Research Grants 2026–2027 Oncodaily